Selective toxicity of engineered lentivirus lytic peptides in a CF airway cell model

Shruti M. Phadke; Kazi Islam; Berthony Deslouches; Sunil A. Kapoor; Donna Beer Stolz; Simon C. Watkins; Ronald C. Montelaro; Joseph M. Pilewski; Timothy A. Mietzner

doi:10.1016/j.peptides.2003.07.001

Selective toxicity of engineered lentivirus lytic peptides in a CF airway cell model

Shruti M. Phadke, Kazi Islam, Berthony Deslouches, Sunil A. Kapoor, Donna Beer Stolz, Simon C. Watkins, Ronald C. Montelaro, Joseph M. Pilewski, Timothy A. Mietzner

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Abstract

Lentivirus lytic peptides (LLPs) are derived from HIV-1 and have antibacterial properties. LLP derivatives (eLLPs) were engineered for greater potency against Staphylococcus aureus (SA) and Pseudomonas aeruginosa (PA). Minimum bactericidal concentration (MBC) was determined in low and physiologic salt concentrations. MBC was decreased against SA and equivalent against PA in physiologic salt when compared to the parent compound LLP1. In a novel cystic fibrosis (CF) airway cell model, one derivative, WLSA5, reduced the number of adherent PA and only moderately affected CF cell viability. Overall, eLLPs are selectively toxic to bacteria and may be useful against CF airway infections.

Original language	English (US)
Pages (from-to)	1099-1107
Number of pages	9
Journal	Peptides
Volume	24
Issue number	8
DOIs	https://doi.org/10.1016/j.peptides.2003.07.001
State	Published - Aug 2003
Externally published	Yes

Keywords

Airway epithelial cells
Antimicrobial peptide
Cystic fibrosis
Selective toxicity

ASJC Scopus subject areas

Biochemistry
Physiology
Endocrinology
Cellular and Molecular Neuroscience

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.peptides.2003.07.001

Cite this

@article{a56095a7991749d7a71dbfad08157b97,

title = "Selective toxicity of engineered lentivirus lytic peptides in a CF airway cell model",

abstract = "Lentivirus lytic peptides (LLPs) are derived from HIV-1 and have antibacterial properties. LLP derivatives (eLLPs) were engineered for greater potency against Staphylococcus aureus (SA) and Pseudomonas aeruginosa (PA). Minimum bactericidal concentration (MBC) was determined in low and physiologic salt concentrations. MBC was decreased against SA and equivalent against PA in physiologic salt when compared to the parent compound LLP1. In a novel cystic fibrosis (CF) airway cell model, one derivative, WLSA5, reduced the number of adherent PA and only moderately affected CF cell viability. Overall, eLLPs are selectively toxic to bacteria and may be useful against CF airway infections.",

keywords = "Airway epithelial cells, Antimicrobial peptide, Cystic fibrosis, Selective toxicity",

author = "Phadke, {Shruti M.} and Kazi Islam and Berthony Deslouches and Kapoor, {Sunil A.} and Stolz, {Donna Beer} and Watkins, {Simon C.} and Montelaro, {Ronald C.} and Pilewski, {Joseph M.} and Mietzner, {Timothy A.}",

year = "2003",

month = aug,

doi = "10.1016/j.peptides.2003.07.001",

language = "English (US)",

volume = "24",

pages = "1099--1107",

journal = "Peptides",

issn = "0196-9781",

publisher = "Elsevier Inc.",

number = "8",

}

TY - JOUR

T1 - Selective toxicity of engineered lentivirus lytic peptides in a CF airway cell model

AU - Phadke, Shruti M.

AU - Islam, Kazi

AU - Deslouches, Berthony

AU - Kapoor, Sunil A.

AU - Stolz, Donna Beer

AU - Watkins, Simon C.

AU - Montelaro, Ronald C.

AU - Pilewski, Joseph M.

AU - Mietzner, Timothy A.

PY - 2003/8

Y1 - 2003/8

N2 - Lentivirus lytic peptides (LLPs) are derived from HIV-1 and have antibacterial properties. LLP derivatives (eLLPs) were engineered for greater potency against Staphylococcus aureus (SA) and Pseudomonas aeruginosa (PA). Minimum bactericidal concentration (MBC) was determined in low and physiologic salt concentrations. MBC was decreased against SA and equivalent against PA in physiologic salt when compared to the parent compound LLP1. In a novel cystic fibrosis (CF) airway cell model, one derivative, WLSA5, reduced the number of adherent PA and only moderately affected CF cell viability. Overall, eLLPs are selectively toxic to bacteria and may be useful against CF airway infections.

AB - Lentivirus lytic peptides (LLPs) are derived from HIV-1 and have antibacterial properties. LLP derivatives (eLLPs) were engineered for greater potency against Staphylococcus aureus (SA) and Pseudomonas aeruginosa (PA). Minimum bactericidal concentration (MBC) was determined in low and physiologic salt concentrations. MBC was decreased against SA and equivalent against PA in physiologic salt when compared to the parent compound LLP1. In a novel cystic fibrosis (CF) airway cell model, one derivative, WLSA5, reduced the number of adherent PA and only moderately affected CF cell viability. Overall, eLLPs are selectively toxic to bacteria and may be useful against CF airway infections.

KW - Airway epithelial cells

KW - Antimicrobial peptide

KW - Cystic fibrosis

KW - Selective toxicity

UR - http://www.scopus.com/inward/record.url?scp=0242495095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242495095&partnerID=8YFLogxK

U2 - 10.1016/j.peptides.2003.07.001

DO - 10.1016/j.peptides.2003.07.001

M3 - Article

C2 - 14612179

AN - SCOPUS:0242495095

SN - 0196-9781

VL - 24

SP - 1099

EP - 1107

JO - Peptides

JF - Peptides

IS - 8

ER -

Selective toxicity of engineered lentivirus lytic peptides in a CF airway cell model

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this